definiens: means ( i ) Epirus ’s proprietary compoundsknown as BOW015, a Biosimilar to infliximab, BOW-050, a Biosimilar to adalimumab, andBOW-070, a Biosimilar to tocilizumab, which are each monoclonal antibodies against TNF - α, and ( ii ) any other proprietary compound Controlled by Epirus or Partner that is added tothis Agreement pursuant to an amendment entered into pursuant to Section 2.5 ( AdditionalLicensed Compounds1.27 means any formulated finished pharmaceuticalproduct that contains a Licensed Compound as an active ingredient and may also containother active ingredients or inactive ingredients ( such as fillers, stabilizers, andpreservatives ), and adjuvants, and includes its delivery system ( i.e. unit dosage formscomprising syringes, vials, tablets, lyophilized powders and cakes, etc . ), as initially identifiedin the Target Product Profile for such Licensed Compound in Exhibit C attached hereto